Kara E, Sakaci T, Ahbap E, Sahutoglu T, Koc Y, Basturk T, Sevinc M, Akgol C, Kayalar A O, Ucar Z A, Unsal A, Seyahi N
Recep Tayyip Erdogan University, Faculty of Medicine, Department of Internal Medicine, Rize, Turkey.
Sisli Etfal Educational and Research Hospital, Department of Nephrology, Istanbul, Turkey.
Transplant Proc. 2016 Jul-Aug;48(6):2065-71. doi: 10.1016/j.transproceed.2016.05.009.
The goal of this study was to evaluate posttransplant urinary tract infection (UTI) rates and graft outcome in kidney transplantation for end-stage renal disease (ESRD) due to vesicoureteral reflux (VUR)-related reflux nephropathy (RN) versus chronic glomerulonephritis (CGN).
A total of 62 patients with ESRD who underwent kidney transplantation for VUR-related RN (VUR-RN group, n = 31; mean ± standard deviation age, 34.1 ± 6.0 years; 58.1% female) or CGN (CGN group, n = 31; mean age, 34.2 ± 6.8 years; 71.0% male) at our unit between January 1996 and January 2011 were included in this retrospective study. Baseline recipient and donor characteristics, renal replacement therapy, posttransplant data on serum creatinine levels, graft outcome, and UTIs were recorded. Posttransplant UTIs and graft outcome were compared between the VUR-RN and CGN groups, as well as between patients with and without pretransplant nephrectomy in the VUR-RN group.
The frequency of overall (72 vs 18 of 90; P = .05) UTI episodes was significantly higher in the VUR-RN group than in the CGN group; Escherichia coli (64.2%) was the most common pathogen. The VUR-RN and CGN groups were similar in terms of 1-year (100.0% for each), 5-year (95.8% vs 96.8%), and 10-year (82.0% vs 96.8%) graft survival. VUR-RN patients with and without nephrectomy were similar in terms of 1-year (100.0% for each), 5-year (91.7% vs 85.7%), and 10-year (81.5% vs 85.7%) graft survival.
Our findings indicate kidney transplantation is a safe and effective option in ESRD patients with RN secondary to VUR. It resulted in high 1-year, 5-year, and 10-year graft survival rates.
本研究的目的是评估因膀胱输尿管反流(VUR)相关反流性肾病(RN)与慢性肾小球肾炎(CGN)导致的终末期肾病(ESRD)患者肾移植术后的尿路感染(UTI)发生率及移植肾结局。
本回顾性研究纳入了1996年1月至2011年1月期间在本单位接受肾移植的62例ESRD患者,其中因VUR相关RN进行肾移植的患者为VUR-RN组(n = 31;平均年龄±标准差,34.1±6.0岁;女性占58.1%),因CGN进行肾移植的患者为CGN组(n = 31;平均年龄,34.2±6.8岁;男性占71.0%)。记录了受者和供者的基线特征、肾脏替代治疗情况、移植术后血清肌酐水平、移植肾结局及UTI相关数据。比较了VUR-RN组和CGN组之间以及VUR-RN组中术前是否行肾切除术患者之间的移植术后UTI发生率及移植肾结局。
VUR-RN组的总体UTI发作频率(90例中有72例 vs 18例;P = 0.05)显著高于CGN组;大肠埃希菌(64.2%)是最常见的病原体。VUR-RN组和CGN组在1年(每组均为100.0%)、5年(95.8% vs 96.8%)和10年(82.0% vs 96.8%)移植肾存活率方面相似。VUR-RN组中行肾切除术和未行肾切除术的患者在1年(每组均为100.0%)、5年(91.7% vs 85.7%)和10年(81.5% vs 85.7%)移植肾存活率方面相似。
我们的研究结果表明,肾移植对于因VUR继发RN的ESRD患者是一种安全有效的选择。其1年、5年和10年移植肾存活率较高。